Endothelial activation and cytokine expression in human acute cardiac allograft rejection

Pathology

Volumn 30, Issue 1, 1998, Pages 24-29

  Salom, Ruth N ^a,b   Maguire, Julie A ^a   Hancock, Wayne W ^c  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b Dorevitch Pathology   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allograft; Cardiac; Cytokines; Endothelium

Indexed keywords

ANTITHROMBIN III; CELL ADHESION MOLECULE; CYTOKINE; FIBRIN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; POLYCLONAL ANTIBODY; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ANTICOAGULATION; AORTA; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL ACTIVATION; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; FEMALE; FIBRIN DEPOSITION; GRAFT REJECTION; HEART GRAFT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE ADHERENCE; MALE; MICROVASCULATURE; PHENOTYPE; PROTEIN EXPRESSION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0031943448     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029800169625     Document Type: Article

References (21)

1. Hengstenberg C, Rose ML, Page C, Taylor PM, Yacoub MH. Immunocytochemical changes suggestive of damage to endothelial cells during rejection of human cardiac allografts. Transplantation 1990; 49: 895-9.
2. Taylor PM, Rose ML, Yacoub MH, Pigott R. Induction of vascular adhesion molecules during rejection of human cardiac allografts. Transplantation 1992; 54: 451-7.
3. Wood KM, Cadogan MD, Ramshaw AL, Parums DV. The distribution of adhesion molecules in human atherosclerosis. Histopathology 1993; 22: 437-44.
4. Li H, Cybulsky MI, Gimbrone MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
5. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537-44.
6. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425.
7. Tsuchida A, Salem H, Thomson N, Hancock WW. Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression. J Exp Med 1992; 175: 81.
8. Hancock WW, Sayegh MH, Sablinski T, Kut JP, Kupiec-Weglinski JW, Milford EL. Blocking of mononuclear cell accumulation, cytokine production and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. Transplantation 1992; 53: 1276-80.
9. Hancock WW, Adams DH, Wyner LR, Sayegh MH, Karnovsky MJ. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle proliferation and carotid occlusion following endothelial injury. Am J Pathol 1994; 145(5): 1008-14.
10. Herbert JM, Savi P, Laplace MC. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 1993; 328: 268-70.
11. Billingham ME, Cary NRB, Hammond EH. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group of the International Society for Heart Transplantation. Heart Transplantation 1990; 9: 587-93.
12. Salom RN, Maguire JA, Esmore D, Hancock WW. Analysis of proliferating cell nuclear antigen expression aids histological diagnosis and is an indicator predictive of progression of cardiac allograft rejection. Am J Pathol 1994; 145, 876-82.
13. Tipping PG, Hancock WW. Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 1993; 142: 1721-8.
14. Hancock WW, Tanaka K, Salem H, Tilney NL, Atkins RC, Kupiec-Weglinski JW. TNF as a mediator of cardiac rejection and effects on the protein C/protein S/thrombomodulin pathway. Transplant Proc 1991; 23: 235-7.
15. Arbustini E, Grasso M, Diegoli M, Bramerio M, Folieni AS, Albertario M, et al. Expression of tumor necrosis factor in human acute cardiac rejection. Am J Pathol 1991; 139: 709-15.
16. Odeh M. Tumor necrosis factor-alpha as a myocardial depressant substance, Int J Cardiol 1993; 42: 3.
17. Tracey KJ, Cerami A. Tumor necrosis factor - a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491.
18. Collins TL, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986; 83: 446.
19. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide induced TNF production in cultured human monocytes, U937 cells and in mice. J Immunol 1989; 143: 3517.
20. Casscells W. Smooth muscle cell growth factors. Prog Growth Fac Res 1991, 3: 177.
21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362: 801.